Company2018-11-04T22:22:13+00:00
Our work

About Voronoi

Voronoi develops novel TPD (Target protein degraders) and kinase inhibitors with the aim to treat intractable and rare diseases. We are developing competitive therapies based on deep understanding of diseases and innovative technologies.

Company structure

Voronoi Group Structure

Voronoi Group consists of the parent company Voronoi and its subsidiaries Voronoi Bio and B2S Bio. Voronoi leads clinical development throughout the R&D journey. Voronoi Bio focuses on R&D of molecular modeling and kinase inhibitor, and B2S Bio focuses on TPD.

People

Meet the experts

Our experts and the management bring to the team years of experience and expertise in various fields.

KoreaUSA